NOS2 and colitis: In vivo:Dose-dependent decrease in monocytes mucosa infiltration.Dose-dependent reduction in TNF-α, IL-1b, IL-6 levels and iNOS gene expression (M1) and increase in IL-10 levels and ARG-1, CD163, IL-10 and PTX-3 gene expression (M2).Decrease in F4/80+CD68+ (activated in colitis model) and boost of F4/80+CD206+.In vitro:Suppression of IL-1b and iNOS genes expression.Normalization of IL-10, PTX3 genes expression. Decrease in IL-1b, TNF-α, IL-6 production and increase in IL-10 levels by 2.5.